Search details
1.
Characterization of structural, biochemical, pharmacokinetic, and pharmacodynamic properties of the LSD1 inhibitor bomedemstat in preclinical models.
Prostate
; 2024 Apr 15.
Article
in English
| MEDLINE | ID: mdl-38619005
2.
Pharmacogenetic and clinical risk factors for bevacizumab-related gastrointestinal hemorrhage in prostate cancer patients treated on CALGB 90401 (Alliance).
Pharmacogenomics J
; 24(2): 6, 2024 Mar 04.
Article
in English
| MEDLINE | ID: mdl-38438359
3.
Phase I Study of Entinostat, Atezolizumab, Carboplatin, and Etoposide in Previously Untreated Extensive-Stage Small Cell Lung Cancer, ETCTN 10399.
Oncologist
; 28(11): 1007-e1107, 2023 Nov 02.
Article
in English
| MEDLINE | ID: mdl-37555284
4.
A PRO-cision medicine intervention to personalize cancer care using patient-reported outcomes: intervention development and feasibility-testing.
Qual Life Res
; 31(8): 2341-2355, 2022 Aug.
Article
in English
| MEDLINE | ID: mdl-35133567
5.
What are survivorship care plans failing to tell men after prostate cancer treatment?
Prostate
; 81(7): 398-406, 2021 05.
Article
in English
| MEDLINE | ID: mdl-33755233
6.
Nivolumab plus ipilimumab, with or without enzalutamide, in AR-V7-expressing metastatic castration-resistant prostate cancer: A phase-2 nonrandomized clinical trial.
Prostate
; 81(6): 326-338, 2021 05.
Article
in English
| MEDLINE | ID: mdl-33636027
7.
End-of-Life Characteristics Associated With Short Hospice Length of Stay for Patients With Solid Tumors Enrolled in Phase I Clinical Trials.
J Natl Compr Canc Netw
; 19(6): 686-692, 2021 01 21.
Article
in English
| MEDLINE | ID: mdl-33477113
8.
Impact of baseline serum IL-8 on metastatic hormone-sensitive prostate cancer outcomes in the Phase 3 CHAARTED trial (E3805).
Prostate
; 80(16): 1429-1437, 2020 12.
Article
in English
| MEDLINE | ID: mdl-32949185
9.
Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery in Patients with High Grade Upper Tract Urothelial Carcinoma.
J Urol
; 203(4): 690-698, 2020 04.
Article
in English
| MEDLINE | ID: mdl-31702432
10.
A phase II randomized trial of RAdium-223 dichloride and SABR Versus SABR for oligomEtastatic prostate caNcerS (RAVENS).
BMC Cancer
; 20(1): 492, 2020 Jun 01.
Article
in English
| MEDLINE | ID: mdl-32487038
11.
Problem Solving to Enhance Clinical Trial Participation Utilizing a Framework-Driven Approach.
Clin Adv Hematol Oncol
; 18(8): 468-476, 2020 Aug.
Article
in English
| MEDLINE | ID: mdl-32903246
12.
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial.
Lancet Oncol
; 20(10): 1370-1385, 2019 10.
Article
in English
| MEDLINE | ID: mdl-31427204
13.
Risk of development of visceral metastases subsequent to abiraterone vs placebo: An analysis of mode of radiographic progression in COU-AA-302.
Prostate
; 79(8): 929-933, 2019 06.
Article
in English
| MEDLINE | ID: mdl-31059588
14.
Genomic and clinical characterization of pulmonary-only metastatic prostate cancer: A unique molecular subtype.
Prostate
; 79(13): 1572-1579, 2019 09.
Article
in English
| MEDLINE | ID: mdl-31389628
15.
Innovations in group-based psilocybin-assisted therapy of major depression in patients with cancer.
Cancer
; 130(7): 1028-1030, 2024 04 01.
Article
in English
| MEDLINE | ID: mdl-38105654
16.
The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER?
Future Oncol
; 15(15): 1683-1695, 2019 May.
Article
in English
| MEDLINE | ID: mdl-30968729
17.
Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study.
Lancet Oncol
; 19(1): 76-86, 2018 01.
Article
in English
| MEDLINE | ID: mdl-29248236
18.
Risk factors for metastatic prostate cancer: A sentinel event case series.
Prostate
; 77(13): 1366-1372, 2017 May.
Article
in English
| MEDLINE | ID: mdl-28786124
19.
Impact of ethnicity on the outcome of men with metastatic, hormone-sensitive prostate cancer.
Cancer
; 123(9): 1536-1544, 2017 05 01.
Article
in English
| MEDLINE | ID: mdl-28055108
20.
Combination of the histone deacetylase inhibitor vorinostat with bevacizumab in patients with clear-cell renal cell carcinoma: a multicentre, single-arm phase I/II clinical trial.
Br J Cancer
; 116(7): 874-883, 2017 Mar 28.
Article
in English
| MEDLINE | ID: mdl-28222071